Business Context and Reporting Period
Company: Karyopharm Therapeutics Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: March 14, 2019
Event: Extension of FDA PDUFA action date for a New Drug Application (NDA).
Key Financial Metrics
This filing is a Current Report (Form 8-K) regarding a regulatory event and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The primary material change reported is the extension of the Prescription Drug User Fee Act (PDUFA) action date by the U.S. Food and Drug Administration (FDA):
- Original PDUFA Date: April 6, 2019
- New PDUFA Date: July 6, 2019
- Duration of Extension: Three months
- Reason: The Company submitted additional, existing clinical information as an amendment to the NDA.
Outlook, Risks, and Management Commentary
Regulatory Status: The NDA seeks accelerated approval for selinexor in combination with dexamethasone for the treatment of patients with relapsed refractory multiple myeloma. The target patient population includes those who have received at least three prior therapies and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-CD38 monoclonal antibody.
Management Action: The Company proactively submitted an amendment to the NDA to facilitate the review process, resulting in the date extension.
Risks: The filing does not explicitly detail new risks, though the extension implies a delay in the potential commercialization timeline for this specific indication.
Investor Verification Checklist
- Verify the specific clinical data submitted in the NDA amendment that necessitated the three-month extension.
- Monitor the July 6, 2019 PDUFA date for the FDA's final decision on accelerated approval.
- Review the full text of the press release filed as Exhibit 99.1 for additional context on the regulatory interaction.
- Assess the impact of the approval delay on the Company's cash burn rate and liquidity position, as this filing does not provide updated financial data.